Umer Raffat gives his take on biotech and discusses Apellis, Teva, Gilead, Vaxcyte, and Bausch Health.

Salim Syed gives his take on biotech and discusses BridgeBio, Cytokinetics, Wave Life Sciences, and Atara Biotherapeutics.

Citi's Neena Bitritto-Garg gives her take on the current state of biotech and recent news about Roivant, Prothena, Amylyx, and Sage.

Christine Brennan, Managing Director of Vertex Ventures HC, highlights neuroscience and other areas of interest in today’s biotech landscape

Brian Skorney discusses biotech's first half of 2023 and recent news from Sarepta, Regeneron, AstraZeneca, Vertex, and Biogen.

Sarah Emond was named president-elect of ICER. She explains her view of ICER’s role and where she sees drug pricing headed in the future.

Anirban Maitra and Shubham Pant from MD Anderson tell us what targets and approaches look promising in pancreatic cancer.

Dr. Jack West walks us through what lung cancer data he is interested in seeing at #ASCO23.

Paul Rennert of Aleta Biotherapeutics gives a rundown on the latest in cell therapies and other modalities ahead of #ASCO23.

Evaluate Vantage's Jacob Plieth previews what to watch for at the 2023 ASCO Annual Meeting in Chicago.

Current BIO Chairman and Nkarta CEO Paul Hastings talks about the policy changes that have been affecting biotech lately, and NK cells.

Dark Horse Consulting's Anthony Davies discusses CMC issues to consider when developing cell and gene therapies.

UPenn's Bruce Levine catches us up on the latest in cell therapy at #ATW23.

UCSF's Nicole Paulk discusses AAV as a gene therapy vector at Advanced Therapies Week in Miami Beach.

Parker Institute's John Connolly provides an update on the latest in cancer immunotherapy at #JPM23.

BTIG biotechnology analyst Justin Zelin gives his take on the news at #JPM23.

Centerview Partners' Eric Tokat talks about the M&A deals that have been announced at #JPM23.

Arie Belldegrun talks about navigating tough times during biotech downturns and allogeneic CAR-T.

Luke Timmerman fills us in on the latest at the Timmerman Report and his upcoming climb for cancer research of Mount Kilimanjaro at #JPM23.

Jorge Conde tells us about a16z's philosophy for investing in healthcare at #JPM23.